<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076476</url>
  </required_header>
  <id_info>
    <org_study_id>P02135</org_study_id>
    <nct_id>NCT03076476</nct_id>
  </id_info>
  <brief_title>Coronary Microcirculatory and Bioresorbable Vascular Scaffolds</brief_title>
  <acronym>EMPIRE-BVS</acronym>
  <official_title>Evaluation of Microcirculatory Protection In Percutaneous REvascularisation With Bioresorbable Vascular Scaffolds Versus Metallic Drug-eluting Stents: a Device- and Implant Technique-based Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Papworth Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Angina and heart attacks are caused by narrowings in the coronary arteries (blood vessels)&#xD;
      supplying the heart. These narrowings can be opened using a balloon and stent (angioplasty).&#xD;
      Traditionally, stents are constructed from metal and are permanent. However, newer stents are&#xD;
      being constructed from carbohydrate polymers (scaffolds), which allow them to reabsorb over&#xD;
      time leaving no permanent implant. New data has suggested that these scaffolds appear to&#xD;
      reduce recurrent angina and may alter the blood flow down the artery. However, it is not&#xD;
      known whether this is due to the scaffolds themselves or the way the scaffolds are inserted.&#xD;
      In this study we hope to measure the blood flow to the heart and assess changes in that flow&#xD;
      during stent and scaffold insertion. It is also important to know whether these effects are&#xD;
      durable and thus, a cohort of patients will return at 3-months to be restudied. These data&#xD;
      are important to help us understand why blood flow is affected by stent/scaffold selection or&#xD;
      device implantation technique and whether this results in better long-term outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IMR between baseline and post-stent/scaffold implantation.</measure>
    <time_frame>During procedure</time_frame>
    <description>IMR: index of microvascular resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CFR between baseline and post-stent/scaffold implantation.</measure>
    <time_frame>During procedure</time_frame>
    <description>CFR: coronary flow reserve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of troponin elevation post-PCI (MI4a).</measure>
    <time_frame>Measured 6 hours after stent insertion</time_frame>
    <description>Measuring serum troponin I levels by blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in IMR between baseline, post-implant and subsequent timepoints in subrandomized group.</measure>
    <time_frame>3 months follow up</time_frame>
    <description>IMR: index of microvascular resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-PCI angina and quality of life by standardized Seattle angina questionnaire at telephone follow-up.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Description: The Seattle Angina Questionnaire is a points based question and answer system where a overall score can be assessed and compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent &amp; scaffold expansion &amp; malapposition adjudged by strut-level OCT analysis.</measure>
    <time_frame>During index procedure and at 3 month follow up</time_frame>
    <description>OCT analysis of stent struts done quantitatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent/scaffold strut coverage/endothelialisation adjudged by strut-level OCT analysis.</measure>
    <time_frame>During index procedure and at 3 month follow up</time_frame>
    <description>OCT analysis of stent struts done quantitatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature/phenotype of underlying target lesion plaque by OCT analysis.</measure>
    <time_frame>During index procedure and at 3 month follow up</time_frame>
    <description>OCT analysis of lesion characteristics done quantitatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At time points 1, 3, 6 &amp; 12 months post-PCI</time_frame>
    <description>Adverse event assessed by clinical history and medical notes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>At time points 1, 3, 6 &amp; 12 months post-PCI</time_frame>
    <description>Serious adverse event assessed by clinical history and medical notes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>CHD - Coronary Heart Disease</condition>
  <condition>Angina, Stable</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>DES-std group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DES-slow group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.&#xD;
After the interim analysis DES-slow to be compared with BVS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BVS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable Vascular Scaffolds (BVS)</intervention_name>
    <description>Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.</description>
    <arm_group_label>BVS group</arm_group_label>
    <other_name>ABSORB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Eluting Stent (DES) - slow</intervention_name>
    <description>Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.&#xD;
After the interim analysis DES-slow to be compared with BVS.</description>
    <arm_group_label>DES-slow group</arm_group_label>
    <other_name>Xience</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Eluting Stent (DES) - standard(std)</intervention_name>
    <description>Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.</description>
    <arm_group_label>DES-std group</arm_group_label>
    <other_name>Xience</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age &gt;18 years, &lt;75 years.&#xD;
&#xD;
          2. Lesion suitability for BVS deployment: target vessel calibre &gt;2.3mm and &lt;3.8mm&#xD;
             reference diameter, without significant tortuosity or calcification.&#xD;
&#xD;
          3. Listed for single-vessel PCI procedure.&#xD;
&#xD;
          4. Lesion length≤28mm (to accommodate single BVS/DES)&#xD;
&#xD;
          5. Preserved left ventricular ejection fraction (EF≥50%).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with confirmed myocardial infarction within the preceding 2 months.&#xD;
&#xD;
          2. Allergy or intolerance to aspirin, clopidogrel, prasugrel or ticagrelor or&#xD;
             contraindication to 12 months' dual antiplatelet therapy.&#xD;
&#xD;
          3. Contraindication to use of adenosine (asthma/chronic lung disease with documented&#xD;
             bronchoreactivity).&#xD;
&#xD;
          4. Significant known comorbidity or terminal condition with life expectancy &lt;6 months.&#xD;
&#xD;
          5. Pregnancy.&#xD;
&#xD;
          6. Coagulopathy or warfarin treatment.&#xD;
&#xD;
          7. Significant renal impairment (baseline creatinine&gt;130 mmol/l).&#xD;
&#xD;
          8. Other comorbid condition that may affect microcirculatory function or troponin release&#xD;
             (eg. Seropositive inflammatory conditions).&#xD;
&#xD;
          9. Inability to comply with follow-up requirements.&#xD;
&#xD;
         10. Target lesion in left mainstem, saphenous vein or arterial grafts.&#xD;
&#xD;
         11. Chronic total occlusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Duckworth</last_name>
    <role>Study Director</role>
    <affiliation>Papworth NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Stent</keyword>
  <keyword>PCI</keyword>
  <keyword>BVS</keyword>
  <keyword>Index of microcirculatory resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

